Albireo Pharma, Inc. ALBO
We take great care to ensure that the data presented and summarized in this overview for ALBIREO PHARMA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALBO
View allLatest Institutional Activity in ALBO
Top Purchases
Top Sells
About ALBO
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Insider Transactions at ALBO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
David Chiswell Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,278
-100.0%
|
-
|
|
Mar 02
2023
|
Simon N.R. Harford CFO and Treasurer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
13,739
-100.0%
|
-
|
|
Mar 02
2023
|
Pamela Stephenson Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,242
-100.0%
|
-
|
|
Mar 02
2023
|
Ronald Harold Wilfred Cooper President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
33,094
-100.0%
|
-
|
|
Mar 02
2023
|
Michelle Graham Chief Human Resources Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,543
-100.0%
|
-
|
|
Mar 02
2023
|
Martha J. Carter Chief Regulatory Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,656
-50.01%
|
-
|
|
Mar 02
2023
|
Jan Mattsson Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
35,524
-100.0%
|
-
|
|
Mar 02
2023
|
Jason Duncan Chief Legal Officer and GC |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,296
-100.0%
|
-
|
|
Jan 23
2023
|
Ronald Harold Wilfred Cooper President and CEO |
SELL
Open market or private sale
|
Direct |
1,057
-1.81%
|
$45,451
$43.8 P/Share
|
|
Jan 23
2023
|
Jason Duncan Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
228
-1.59%
|
$9,804
$43.8 P/Share
|
|
Jan 23
2023
|
Simon N.R. Harford CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
102
-0.31%
|
$4,386
$43.8 P/Share
|
|
Jan 23
2023
|
Jan Mattsson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
197
-0.36%
|
$8,471
$43.8 P/Share
|
|
Jan 23
2023
|
Michelle Graham Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
102
-0.41%
|
$4,386
$43.8 P/Share
|
|
Jan 23
2023
|
Pamela Stephenson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
102
-0.24%
|
$4,386
$43.8 P/Share
|
|
Jan 23
2023
|
Martha J. Carter Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
120
-0.82%
|
$5,160
$43.8 P/Share
|
|
Jan 19
2023
|
Jason Duncan Chief Legal Officer and GC |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+44.3%
|
-
|
|
Jan 19
2023
|
Martha J. Carter Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+44.17%
|
-
|
|
Jan 19
2023
|
Jan Mattsson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+33.44%
|
-
|
|
Jan 19
2023
|
Ronald Harold Wilfred Cooper President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
195,000
+43.58%
|
-
|
|
Jan 19
2023
|
Paul Streck Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+31.62%
|
-
|